obesity

News

Lilly's GLP-1s race away in Q2, though Foundayo falls short

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.

News

Lilly plans Q1 2027 filing for obesity triple retatrutide

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Novo's Wegovy pill cleared for weight loss in EU

The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.

News

Kailera's big obesity reveal puts pressure on shares

Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.

News

Kalohexis chief executive Russell Potterfield

Obesity biotech Kalohexis files confidential IPO

Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.

Lilly's GLP-1s race away in Q2, though Foundayo falls short

US judge says Novo Nordisk must face lawsuit over CagriSema

Lilly plans Q1 2027 filing for obesity triple retatrutide

Novo's Wegovy pill cleared for weight loss in EU

Kailera's big obesity reveal puts pressure on shares

Obesity biotech Kalohexis files confidential IPO

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks